Forbion Capital Partners

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

Forbion Capital Partners, established in 2006 and headquartered in Europe., specializes in Late Stage Venture, Early Stage Venture, Private Equity, Seed investments across Health Care, Medical Device, Hospital, Financial Services, Venture Capital, Finance, Biotechnology, Pharmaceutical, Medical, Manufacturing. The organization boasts a portfolio of 141 investments, with an average round size of $56.6M and 47 successful exits. Their recent investments include CircuLite, Omnes Capital, Oxford Bioscience Partners, Foundation Medical Partners, Pathway Medical Technologies. The highest investment round they participated in was $690.0B. Among their most notable exits are CircuLite and Omnes Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.